Pradaxa Lawyers Reviewing Cases of Serious Internal Bleeds, Hemorrhaging
The product liability lawyers at Saiontz & Kirk, P.A. previously reviewed potential Pradaxa lawsuits for individuals throughout the United States who have experienced severe internal bleeding or hemorrhaging, including gastrointestinal (GI) bleeds, brain hemorrhage, kidney bleeding, death or other bleeding problems.
Pradaxa (dabigatran) is a relatively new blood thinner that was just approved in October 2010. Due to aggressive marketing, the medication was widely used almost immediately, with a reported 86,000 people receiving a prescription during the first three months it was on the market.
The FDA approved Pradaxa for prevention of strokes among patients with atrial fibrillation, which may carry a risk of blood clots due to the irregular contraction of blood through the heart. However, Pradaxa has also been widely used off-label as a blood thinner for other conditions, with some reports suggesting that only about 1/3rd of the use during the first three months was for the approved use.
Although Pradaxa was marketed as a superior medication over warfarin, a blood thinner that has been on the market for decades, it now appears that the manufacturer failed to adequately disclose the extent of the risk of Pradaxa bleeding side effects.
Pradaxa was marketed as easier to use than warfarin because it requires less monitoring. However, when users of warfarin experience abnormal bleeding, the side effect can be counteracted with Vitamin K and there is no similar solution for Pradaxa bleeding problems.